CYP19A1 and invasive breast carcinoma: As a result of these potential toxicities, as well as the beneficial effect of aromatase inhibitors in the adjuvant treatment of hormone-responsive invasive breast cancer, the NSABP is conducting the B-35 trial designed to compare the effects of tamoxifen and an aromatase inhibitor, anastrozole, on the occurrence of local, regional, distant, or contralateral breast cancer.